The Neuropsychiatry of 22q11.2 Deletion Syndrome: An Electronic Health Records Study.

Abstract

Background22q11.2 deletion syndrome (22q11.2DS) is the commonest chromosomal microdeletion disorder. Varied neuropsychiatric manifestations have been identified, though often in clinically ascertained cohorts. We aimed to characterise the neuropsychiatric phenotype of 22q11.2DS at unprecedented scale using routinely collected electronic health records. MethodsWe conducted a retrospective observational study using the TriNetX Global Collaborative Network. We identified 10,831 individuals with repeated clinical codes consistent with 22q11.2DS and compared them with propensity score-matched healthcare controls, estimating the prevalence and odds of recorded neurodevelopmental, psychiatric and neurological diagnoses. We also characterised the clinical profiles of 22q11.2DS-associated autism spectrum and psychotic disorders. ResultsNeurodevelopmental disorders were over-represented in 22q11.2DS, including intellectual disability (OR: 33{middle dot}2 [95% CI 24{middle dot}4-45{middle dot}2]), autism spectrum disorder (OR: 5{middle dot}4 [4{middle dot}6-6{middle dot}2]) and developmental language disorder (OR: 6{middle dot}1 [5{middle dot}6-6{middle dot}7]). In adults, the neuropsychiatric burden of 22q11.2DS was substantial, with schizophrenia (OR: 21{middle dot}3 [11{middle dot}6-39{middle dot}1]), epilepsy (OR: 10{middle dot}9 [8{middle dot}5-14{middle dot}0]) and personality disorders (OR: 3{middle dot}8 [2{middle dot}4-6{middle dot}1]) among the strongest associations. Catatonia (OR: 18{middle dot}5 [13{middle dot}0-26{middle dot}4]) as well as dissociative and functional neurological disorders (OR: 2{middle dot}5 [1{middle dot}5-4{middle dot}2]) were also enriched compared with controls, while several movement disorders remained more common despite additional matching on antipsychotic exposure. Among 13 individuals with 22q11.2DS and a recorded diagnosis of Parkinsons disease, 10 were first diagnosed before age 50. Comparisons between 22q11.2DS-associated and non-22q11.2DS psychotic and autism spectrum disorders revealed differences in comorbidity and clinical outcomes. ConclusionsIn the largest electronic health records study of 22q11.2DS to date, we reveal a profound neuropsychiatric burden and demonstrate the potential of routinely collected health data to advance understanding of rare disorders.